THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

The magnitude of the reduction in prostate cancer deaths from population-based PSA screening is too small for a clinical and public health benefit. PSA screening of the general male population ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

SEPTEMBER IS PROSTATE CANCER AWARENESS AND A GOOD REMINDER FOR MEN TO KNOW THEIR SCORE. WELL, JOINING US LIVE THIS MORNING, TWO TIME PROSTATE CANCER SURVIVOR AND AMERICAN CANCER SOCIETY VOLUNTEER ...